ANAB Quote, Financials, Valuation and Earnings

Adaptive Biotechnologies Corp. has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of -18.94%. AnaptysBio, Inc.'s return on equity of -97.37% beat Adaptive Biotechnologies Corp.'s return on equity of -29.68%.

AnaptysBio, Inc. has a consensus price target of $79.91, signalling upside risk potential of 38.22%. On the other hand Adaptive Biotechnologies Corp. has an analysts' consensus of $20.86 which suggests that it could grow by 40.83%. Given that Adaptive Biotechnologies Corp. has higher upside potential than AnaptysBio, Inc., analysts believe Adaptive Biotechnologies Corp. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.400, which suggesting that the stock is 59.994% less volatile than S&P 500. In comparison Adaptive Biotechnologies Corp. has a beta of 2.293, suggesting its more volatile than the S&P 500 by 129.292%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptive Biotechnologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Adaptive Biotechnologies Corp. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $108.2M, which are larger than Adaptive Biotechnologies Corp. quarterly revenues of $71.7M. AnaptysBio, Inc.'s net income of $49.6M is higher than Adaptive Biotechnologies Corp.'s net income of -$13.6M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Adaptive Biotechnologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.52x versus 8.48x for Adaptive Biotechnologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of -165.45%. AnaptysBio, Inc.'s return on equity of -97.37% beat Nektar Therapeutics's return on equity of -364.32%.

AnaptysBio, Inc. has a consensus price target of $79.91, signalling upside risk potential of 38.22%. On the other hand Nektar Therapeutics has an analysts' consensus of $128.13 which suggests that it could grow by 66.42%. Given that Nektar Therapeutics has higher upside potential than AnaptysBio, Inc., analysts believe Nektar Therapeutics is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.400, which suggesting that the stock is 59.994% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.165, suggesting its more volatile than the S&P 500 by 16.45%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $108.2M, which are larger than Nektar Therapeutics quarterly revenues of $21.8M. AnaptysBio, Inc.'s net income of $49.6M is higher than Nektar Therapeutics's net income of -$36.1M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.52x versus 93.68x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of 40.17%. AnaptysBio, Inc.'s return on equity of -97.37% beat Rigel Pharmaceuticals, Inc.'s return on equity of 299.43%.

AnaptysBio, Inc. has a consensus price target of $79.91, signalling upside risk potential of 38.22%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.20 which suggests that it could grow by 85.98%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.400, which suggesting that the stock is 59.994% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.172%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $108.2M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.8M. AnaptysBio, Inc.'s net income of $49.6M is lower than Rigel Pharmaceuticals, Inc.'s net income of $268.1M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 1.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.52x versus 1.77x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of -246.76%. AnaptysBio, Inc.'s return on equity of -97.37% beat Vanda Pharmaceuticals, Inc.'s return on equity of -47.32%.

AnaptysBio, Inc. has a consensus price target of $79.91, signalling upside risk potential of 38.22%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $15.50 which suggests that it could grow by 121.43%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..

AnaptysBio, Inc. has a beta of 0.400, which suggesting that the stock is 59.994% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.293%.

AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

AnaptysBio, Inc. quarterly revenues are $108.2M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $57.2M. AnaptysBio, Inc.'s net income of $49.6M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$141.2M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.52x versus 1.89x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.